A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older With an Extension Phase of 12 Months

Trial Profile

A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older With an Extension Phase of 12 Months

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Bis-choline tetrathiomolybdate (Primary)
  • Indications Hepatolenticular degeneration
  • Focus Therapeutic Use
  • Sponsors Wilson Therapeutics
  • Most Recent Events

    • 24 Oct 2017 Preliminary results of 24 to 48-week data from the ongoing extension period of the study, presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top